Skip to main content

Rituximab vs. Tocilizimab for Scleroderma: Which is Better?

Dr. Janet Pope discusses abstract OP0295 presented at Eular 2024 in Vienna, Austria.

ADD THE FIRST COMMENT

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

×